A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab

Annals of the Rheumatic Diseases

Volumn 73, Issue 7, 2014, Pages 1429-1430

  Ray, Manoj ^a   Curtis, Jeffrey R ^b   Baddley, John W ^a  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE;

AGED; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COORDINATION DISORDER; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SAFETY; DYSARTHRIA; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; LETTER; LEUKOENCEPHALOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; WHITE MATTER LESION;

ANTI-TNF; INFECTIONS; RHEUMATOID ARTHRITIS; TREATMENT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRAIN; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; NERVE FIBERS, MYELINATED; OPPORTUNISTIC INFECTIONS;

EID: 84902279363     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204978     Document Type: Letter

References (8)

1. Tan CS, Koralnik IJ, et al. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-37.
2. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430-8.
3. Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken) 2012;64:612-15.
4. Arkema EV, van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: A national population-based study. Ann Rheum Dis 2012;71:1865-7.
5. Berger JR, et al. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010;33:969-83.
6. Kuhle J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCRnegative PML in a natalizumab-treated patient with MS. Neurology 2011;77:2010-6.
7. Molloy ES, et al. PML and rheumatology: The contribution of disease and drugs. Cleve Clin J Med 2011;78(Suppl 2):28-32.
8. Keene DL, Legare C, Taylor E, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011;38:565-71.